DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The move follows promising but early data presented at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.